Format

Send to

Choose Destination
J Infect Dis. 2017 Mar 15;215(suppl_3):S152-S159. doi: 10.1093/infdis/jiw555.

Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection.

Ferrari G1,2,3, Pollara J1,3, Tomaras GD1,4,2,3, Haynes BF5,4,3.

Author information

1
Departments of Surgery.
2
Molecular Genetics and Microbiology and.
3
Duke Human Vaccine Institute, Duke University, Durham, North Carolina.
4
Immunology, and.
5
Medicine.

Abstract

Human immunodeficiency virus (HIV) type 1 uses the CD4 molecule as its principal receptor to infect T cells. HIV-1 integrates its viral genome into the host cell, leading to persistent infection wherein HIV-1 can remain transcriptionally silent in latently infected CD4+ T cells. On reactivation of replication-competent provirus, HIV-1 envelope glycoproteins (Env) are expressed and accumulate on the cell surface, allowing infected cells to be detected and targeted by endogenous immune responses or immune interventions. HIV-1 Env-specific antibodies have the potential to bind HIV-1 cell surface Env and promote elimination of infected CD4+ T cells by recruiting cytotoxic effector cells, such as natural killer cells, monocytes, and polymorphonuclear cells. Harnessing humoral and innate cellular responses has become one focus of research to develop innovative strategies to recruit and redirect cytotoxic effector cells to eliminate the HIV-1 latently infected CD4+ T-cell reservoir.

KEYWORDS:

ADCC; Antibodies; HIV-1; bispecific antibodies; cure.; innate immunity; latency

PMID:
28520963
PMCID:
PMC5410976
DOI:
10.1093/infdis/jiw555
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center